Pharmaceuticals
Quarterly Result9 April 2026 at 01:31 pm

Laurus Labs Ltd to Approve Audited Financial Results for FY 2025-26 and Consider 2nd Interim Dividend

AI Summary

Laurus Labs Ltd has announced that its Board of Directors will meet on April 30, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The meeting will also consider the proposal for payment of the 2nd Interim Dividend for FY 2025-26 and fix the record date for determining the eligibility of shareholders. The trading window for dealing in securities by the Directors and Designated Persons has been closed from April 01, 2026, and will remain closed till May 02, 2026.

Key Highlights

  • Laurus Labs Ltd to consider and approve audited financial results for Q4 and FY 2025-26
  • Consideration of proposal for payment of 2nd Interim Dividend for FY 2025-26
  • Fixation of record date for determining the eligibility of shareholders
  • Trading window for dealing in securities by Directors and Designated Persons closed from April 01, 2026, to May 02, 2026